You just read:

Aeterna Zentaris Announces Interim Data for its Phase 1/2 Trial with AEZS-108 in Prostate Cancer at ESMO Congress - AEZS-108 well tolerated at all dose levels / Early evidence of anti-tumor activity

News provided by

AETERNA ZENTARIS INC.

Sep 26, 2011, 07:00 ET